The theoretical innovation and new drug research on the prevention and treatment of cardiovascular diseases by activating blood circulation has been one of the most active and outstanding achievements in the field of integrated Chinese and western medicine for the past 60 years. Research on blood stasis syndrome (BSS) and activating blood circulation (ABC) was the first to be awarded the first prize of National Award for Science and Technology Progress in Chinese Medicine since the founding of the People's Republic of China. The research team headed by prof. Keji CHEN has obtained abundant research achievements. Taking coronary heart disease, a major clinical cardiovascular disease as the entry point, the team explored the development of the diagnostic criteria for the combination of BSS, the interpretation of the modern connotation of ABC, the development of a series of new drugs for ABC, clinical efficacy evaluation and mechanism of its action. It promotes the standardization and internationalization of traditional Chinese medicine and forms high-quality evidence for clinical transformation. It has also made outstanding contributions to the prevention and treatment of cardiovascular diseases with original features. In this paper, the history of prevention and treatment of cardiovascular diseases by ABC after the founding of the People's Republic of China was reviewed. The representative research findings of several domestic academic teams, including prof. Keji CHEN's team, over the past 60 years were expounded emphatically so as to provide reference for promoting and innovating research in activating blood circulation and removing blood stasis.
ObjectiveTo systematically review the relationship between systemic immune inflammatory index (SII) and the prognosis of coronary heart disease. MethodsThe CNKI, VIP, CBM, WanFang Data, PubMed, EMbase, Web of Science, Ovid, Cochrane Library and Scopus databases were electronically searched to collect cohort studies related to the relationship between SII and the prognosis of patients with coronary heart disease from inception to December 10, 2022. Two researchers independently screened the literature, extracted the data and assessed the risk of bias of the included studies. Meta-analysis was then performed by using RevMan 5.3 and Stata 15.0 software. ResultsA total of 7 cohort studies involving 18 413 patients were included. The results of meta-analysis showed that the group of high level SII was higher risk of major adverse cardiovascular events (MACE) (OR=2.2, 95%Cl 1.5 to 3.3, P<0.01), all-cause death (OR=2.0, 95%Cl 1.1 to 3.4, P=0.02), and cardiogenic death (OR=2.4, 95%Cl 1.5 to 3.9, P<0.01) than the group of low level SII. However, no significant difference was found in the risk of re-hospitalization for heart failure. ConclusionThe current evidence shows that high levels of SII can increase the risk of MACE, all-cause death and cardiogenic death in patients with coronary heart disease. Due to the limited quality and quantity of the included studies, more high quality studies are needed to verify the above conclusion.